Pain · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Physical function · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Quality of life · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Participant‐reported global assessment · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Radiographic joint changes · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Adverse events · Patients with osteoarthritis of the knee or hip
Summary of findings table ‐ Adjunctive therapies in addition to… showed no clear difference in adverse events compared with placebo adjunctive therapies (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Mean change in pain from baseline (0‐ to 10‐point scale, 0 is no pain) at 8–16 weeks · predominantly knee osteoarthritis
Antidepressant showed no clear difference in mean change in pain from baseline (0‐ to 10‐point scale, 0 is no… compared with placebo (high certainty).
1 finding from 1 review
At least 50% reduction in pain · predominantly knee osteoarthritis
Antidepressant leads to higher responder rate: ≥ 50% reduction in 24‐hour mean pain compared with placebo (high certainty).
1 finding from 1 review
Physical function · predominantly knee osteoarthritis
Antidepressant showed no clear difference in mean change in physical function from baseline (0–100 WOMAC Total… compared with placebo (high certainty).
1 finding from 1 review
Quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0 indicates perfect health) between 0 and 14 weeks · predominantly knee osteoarthritis
Antidepressant probably leads to higher quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants who withdrew due to adverse events between 0 and 14 weeks · predominantly knee osteoarthritis
Antidepressant probably leads to higher proportion of participants who withdrew due to adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant leads to higher total adverse events between 0 and 16 weeks compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant showed no clear difference in serious adverse events between 0 and 16 weeks compared with placebo (low certainty).
1 finding from 1 review
Cognitive function · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Major bleeding (intracranial and extracranial) · people with cerebral small vessel disease and no dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional ability · people with cerebral small vessel disease and no dementia
1 finding from 1 review
Stroke or transient ischaemic attack · people with cerebral small vessel disease and no dementia
1 finding from 1 review
Any adverse events (excluding major bleeding) · people with cerebral small vessel disease and no dementia
1 finding from 1 review
Withdrawal from study medication · people with cerebral small vessel disease and no dementia
1 finding from 1 review